Literature DB >> 10431775

Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.

P J Visser1, P Scheltens, F R Verhey, B Schmand, L J Launer, J Jolles, C Jonker.   

Abstract

To determine whether the medial temporal lobe is atrophic in subjects with mild cognitive impairment, and whether atrophy of this structure is a better predictor of dementia than memory dysfunction. Forty-five noninstitutionalized subjects aged 65-85 years were randomly selected from a population based study to obtain a sample with Alzheimer's disease (AD; n = 7), and a clinically nondemented sample (n = 38). Twenty of the latter subjects displayed some cognitive impairment and fulfilled CAMDEX criteria for "minimal dementia." Coronal T1-weighted magnetic resonance imaging was used to visualize the medial temporal lobe. The volume of the parahippocampal gyrus and hippocampus was measured, and medial temporal lobe atrophy was assessed qualitatively. The memory subscore from the CAMCOG was used as a measure of memory functioning. The follow-up period was 3 years. Nine subjects who were diagnosed as being minimally demented at baseline met the criteria for AD during follow-up. At baseline the volume of the parahippocampal gyrus of these subjects was smaller than that of the other subjects with minimal dementia. The memory score was the best predictor of clinical outcome. All medial temporal lobe measures increased the accuracy of prediction compared with only the memory score, by reducing the number of false-negative classifications of dementia. Severe medial temporal lobe atrophy is present even in some subjects with mild cognitive impairment and is an indicator of subsequent AD. The absence of medial temporal lobe atrophy, however, does not exclude the development of dementia. In the majority of subjects memory impairment was a better predictor of dementia than atrophy of the medial temporal lobe. The combination of the two increased predictive accuracy. Nondemented subjects with severe atrophy of the medial temporal lobe could be enrolled in drug trials aimed at slowing the progression of AD.

Entities:  

Mesh:

Year:  1999        PMID: 10431775     DOI: 10.1007/s004150050387

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  79 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 2.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 3.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

4.  Medial temporal lobe function and structure in mild cognitive impairment.

Authors:  Bradford C Dickerson; David H Salat; Julianna F Bates; Monika Atiya; Ronald J Killiany; Douglas N Greve; Anders M Dale; Chantal E Stern; Deborah Blacker; Marilyn S Albert; Reisa A Sperling
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

5.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

6.  Longitudinal volumetric MRI change and rate of cognitive decline.

Authors:  D Mungas; D Harvey; B R Reed; W J Jagust; C DeCarli; L Beckett; W J Mack; J H Kramer; M W Weiner; N Schuff; H C Chui
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

7.  Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Lubov E Zeifman; William F Eddy; Oscar L Lopez; Lewis H Kuller; Cyrus Raji; Paul M Thompson; James T Becker
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

Authors:  C R Jack; M M Shiung; S D Weigand; P C O'Brien; J L Gunter; B F Boeve; D S Knopman; G E Smith; R J Ivnik; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

Review 9.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 10.  Mild cognitive impairment: ten years later.

Authors:  Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack
Journal:  Arch Neurol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.